Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Pharmaceutical Investing Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides Clinical Update
Pharmaceutical Investing Corcept Therapeutics Announces First Quarter 2018 Financial results and Provides Corporate Update
Pharmaceutical Investing Corcept Therapeutics Files Lawsuit Against Teva Pharmaceuticals for Infringement of Korlym Patents
Pharmaceutical Investing Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
